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Abstract
We propose to make use of the wealth of underused DNA chip data available in public repositories to study the molecular
mechanisms behind the adaptation of cancer cells to hypoxic conditions leading to the metastatic phenotype. We have
developed new bioinformatics tools and adapted others to identify with maximum sensitivity those genes which are
expressed differentially across several experiments. The comparison of two analytical approaches, based on either Over
Representation Analysis or Functional Class Scoring, by a meta-analysis-based approach, led to the retrieval of known
information about the biological situation – thus validating the model – but also more importantly to the discovery of the
previously unknown implication of the spliceosome, the cellular machinery responsible for mRNA splicing, in the
development of metastasis.
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Introduction
Cancer & metastasis
Despite the development of effective therapies for many cancers
[1-3], the prevalence of cancer is growing alarmingly in aging
populations [4]. Metastases are one of the main causes of death
related to cancer [5]. It is therefore not surprising that a large
number of labs and researchers focus on gaining a better
understanding of the metastatic process [6–8].
Cancer is known to be a genetic disease, implying either
alteration of DNA or dysregulation of gene expression [9]. In
addition, the metastatic phenotype involves the combination of
several factors [7], among which a hypoxic micro-environment has
been reported to be a major/key parameter [10–12]. Several
hypotheses have been proposed to explain this observation. First, a
mechanism of adaptation is initiated, mediated by the HIF-1
transcription factor, to enhance cell survival [13]. Second, the cell
response to hypoxic conditions also triggers the angiogenesis
process [14]. Lastly, hypoxia has been reported to affect the
selection of high potential metastatic cells [15]. As this manuscript
focuses on the bioinformatics analysis of the data, we direct the
reader to the following reviews for a more detailed discussion of
the role of hypoxia in the development of metastasis [16–18].
Microarrays
In the last decade, the availability of microarray datasets in
public repositories has grown dramatically (i.e. ArrayExpress [19],
GEO [20]...). As an example, the number of datasets in the Gene
Expression Omnibus (GEO) has increased from 2,000 to more
than 780,000 over the last ten years (2002–2012). Previously, most
researchers focused on a small handful of probe sets spotted on the
arrays, ignoring thousands of other probe sets. Despite the
financial cost associated with creating large collections of public
datasets (millions of euros/dollars), the incomplete and/or partial
analysis of the datasets consequently suggests that a large body of
underexploited information could be put to use in further analyses.
Many authors has also significantly improved the performance of
statistical analyses by solving methodological issues [21–23], and
developing the alternative chip definition file (CDF) [24]. We
propose to make use of this wealth of information by including
several microarray datasets, from experiments studying similar/
common biological issues, in a single analytical pipeline that makes
use of the latest and best-performing algorithms, without
preconceived biases.
Data preparation
Datasets must be preprocessed in preparation for statistical
analysis to improve the quality of the data (background
correction), to allow for a fair comparison between arrays
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(standardization), and to summarize probe-level intensities to
meaningful probe set values [25,26]. Several benchmarks have
previously been reported to assess the performances of preproces-
sing methods [27,28].
The last preprocessing step, called summarization, consists of
gathering probe-level information regarding the same target. The
mapping of the target definition to the probe coordinates on the
chips involves a chip definition file (CDF). The annotation of the
human genome has improved since the first release of CDFs by the
manufacturer (Affymetrix) and several authors have thus reported
the need to update the definition of chip definition files [29,30]. In
2007, Liu et al described the affyprobeminer as a tool to ease the
mapping of current knowledge to probe sequences in Affymetrix
arrays [24]. The authors reported discrepancies ranging from 30
to 50% between standard Affymetrix and remapped chip
definition files. Affyprobeminer can also be used to build both
transcript- and gene-consistent CDFs, meaning that a probe-set is
defined to gather probes that specifically target only one transcript,
or gene, respectively.
Single gene analysis of one dataset
Microarray data can be used to track the expression profile of
the transcriptome following a hierarchical strategy that involves
many levels of interpretation. The first level refers to individual
analyses aimed at inferring the positive/negative regulation of
transcripts and/or genes, as defined in the chip definition file
(probe set definition in CDF). Wet-lab biologists mainly interpret
microarray experiments based on the results of this step.
Additional layers of analysis are described briefly in the next
subsections (meta-analysis and gene set analysis).
In previous work, we described a relationship between the
number of replicates and the selection of the best performing
methods [31]. The two main results are that the best method
overall is the Shrinkage t test [22], bested solely by the Window t
test [32] and Regularized t test [21] when only two replicates are
available; the other main result is that the overall power of such
an analysis is relatively low, depending on the number of
replicates available. Therefore, the authors claimed that future
methodological developments should focus on augmenting that
power and on an appropriate filtering of the results.
Annotation of a list of candidate genes
After the individual analyses, the list of genes detected as
differentially expressed is typically annotated using over-represen-
tation analysis (ORA) methods to highlight meaningful informa-
tion. In a previous work, we described the use of the DAVID
webtools to perform such an analysis on the results of microarray
studies [33]. The DAVID webtool analyzes the list of differentially
expressed genes and returns a list of the pathways containing part
of these genes, associated with an over-representation score (EASE
score) [34].
Differential expression analysis of gene sets
Small datasets with only a few replicates are still a major
hindrance to statistical power in conventional analyses. Gene set
analysis and meta-analysis are interesting and common ways to
extract more information from the data, and to test higher-level
hypotheses with a power level associated with an increased
number of available values.
Gene set analysis using Functional Class Scoring methodologies
(FCS) has improved the understanding of differences in expression
profiles, and helped unravel the biological processes underlying
experimental data in several ways. First, joint analysis of multiple
genes involves a higher number of values than individual analyses,
hence providing the potential for a higher power level, even when
conducted on small datasets (small number of replicates). Second,
computation of differential expression from multiple levels of
interpretation enriches the qualitative description of biological
variations between experimental conditions. The criteria used to
define the gene sets consequently guide interpretation of the results
(i.e. regulation element/transcription factor, metabolic pathways,
pathology signatures, locus, cellular components...). By extension,
the comparison of the results of individual and gene set analyses
allows, as with ORA methods, to refine the list of candidate genes
for further testing, thanks to the criteria-based approach (i.e. if all
but one gene of a set of related genes are detected as "silenced" due
Figure 1. Summary of the analytical pipeline.
doi:10.1371/journal.pone.0086699.g001
A Bioinformatics Analysis of Micrarray Data
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to deletion, one can remove this potential false negative or screen
the genome for an additional copy of the gene).
Over the last decade, various Functional Class Scoring
methodologies (FCS) have been developed to analyze gene sets,
including 2-step or global methods, competitive or self-contained
null hypothesis and inference (gene-sampling, label-sampling...):
GSEA [35,36], SAMGS [37], GlobalTest, [38]...
Method-specific biases in the detection of gene sets are
associated with methodological choices, and are due to correla-
tions between genes, the simultaneous presence of up/down
regulated genes, the level of expression and the number of genes in
the set.... In order to detect all kinds of sets with an expression
profile that differs between conditions, we developed FAERI,
tailored from the two-way ANOVA [39]. Prior to analysis, FAERI
applies a 2-step data reduction to avoid previously observed biases.
The null distribution can then be evaluated from simulations or
sample permutations. Performance comparisons conducted both
on simulated and biological data illustrate that FAERI, evaluated
using sample permutations, provides the most accurate results
versus other methods, regardless of the composition of the gene
sets (in terms of direction, level of expression, correlation and
proportion of DEGs in the set). Mansmann and Meister similarly
Table 1. List of the 16 datasets used in this manuscript.
Dataset Identifier Number of replicates (Control + Tests) Biological context
E-MEXP-445 6 (3+3) Normoxia vs. hypoxia (monocytes)
GSE4725 6 (2+4) Normoxia vs. hypoxia (arterial smooth muscle cells)
GSE11341 23 (6+17) Normoxia vs. hypoxia (lung cells)
E-MEXP-1896 4 (2+2) Normoxia vs. hypoxia (HEK293T cells)
GSE4086 4 (2+2) Normoxia vs. hypoxia (lymphocytes B)
GSE5579 4 (2+2) Normoxia vs. hypoxia (lymphatic endothelial cells)
GSE9234 6 (3+3) Normoxia vs. hypoxia (HT-29 cells)
E-GEOD-1323 6 (3+3) Primary tumor vs. metastasis (colon cancer cell lines)
E-GEOD-2280 27 (8+19) Primary tumor vs. metastasis (lymph node cells)
GSE7929 32 (21+11) Primary tumor vs. metastasis (A 375 metastatic cell line)
GSE7930 6 (3+3) Primary tumor vs. metastasis (prostate subcutaneous tumors)
GSE7956 39 (29+10) Primary tumor vs. metastasis (A 375 metastatic cell line)
GSE8401 83 (31+52) Primary tumor vs. metastasis (melanoma cells)
GSE3325 19 (13+6) Primary cancer vs. metastasis (prostate cancer cells)
GSE8977 22 (15+7) Primary cancer vs. metastasis (breast cancer cells)
GSE9576 12 (9+3) Primary cancer vs. metastasis (Midgut carcinoid liver cells)
doi:10.1371/journal.pone.0086699.t001
Figure 2. Volcano plots for two datasets. Each volcano plot is related to a single data set, chosen among the different technologies and
biological group tested. The green bars represent fold change log2 values of +–2 and the blue bar represent a p-value threshold of 0.05. The red dots
are the 1156 genes selected in the meta-analysis step.
doi:10.1371/journal.pone.0086699.g002
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reported that sample permutations of microarray data should be
preferred for evaluation of the null distribution in the GlobalAn-
cova methodology, due the variability observed with real samples
[40]).
Meta-analysis
Meta-analysis is a natural extension of the dataset-based analysis
conducted using individual and gene set methodologies, and
examines several datasets relating to similar experimental condi-
tions. A meta-analysis strategy was reported previously by
Simpsons et al in 1904 [41] and has been extensively used in the
field of medical sciences [42–44].
To identify commonly regulated genes in multiple datasets, a
higher-level analysis must be defined as opposed to the
dataset-specific strategies described above. The ideal meta-analysis
design would consist of the joint analysis of multiple datasets
following a higher-order multivariate analysis procedure. How-
ever, post-hoc strategies require less computing time than full-on
transversal analyses, which still remains a major concern in the
analysis of large datasets. In a previous study, we explored an
intersection-based post-hoc strategy, defined as an additional
analytical step performed on results generated with several dataset-
specific analyses [45].
To compare the results of differential expression analyses of
genes (or gene sets) across datasets, we reported use of the number
of dataset-specific analyses that result in a significant detection of
the gene (the number of top-lists in which each gene is present).
This score, which monitors systematic differences in expression
profiles across datasets, was then used as a selection criterion to
define candidate genes. The reported strategy leads to three
situations, depending on the strictness of the comparison across
datasets: 1) the selection of genes that are detected in all (or the
highest number of) datasets (intersection of all top-lists) results in a
very low number of genes, which are often already well known; 2)
selection of the genes detected in at least one dataset (union of all
top lists) results in too many candidates for further investigation,
and does not exclude false positives; 3) a balance can be reached
between both situations, with an intermediate selection threshold
at the number of DEGs across datasets. That intermediate
situation (union of intersections between a given number of top
lists) allows for inference of a workable amount of new candidates.
Along these lines, several techniques have been developed to
describe the intersections between lists of genes [33,45,46].
Table 2. List of pathways identified by DAVID with either a significant p-value or 14 or more genes of the 1156 DEG list detected in
the map.
Pathway Count EASE score Benjamini FDR
Spliceosome 30 2.15E-07 3.75E-05 2.64E-04
Cell Cycle 25 6.33E-05 5.49E-03 7.75E-02
Glycolysis / Gluconeogenesis 14 9.55E-04 4.07E-02 1.16E+00
Aminoacyl-tRNA biosynthesis 10 5.21E-03 1.66E-01 6.19E+00
Pentose phosphate pathway 7 1.39E-02 2.93E-01 1.57E+01
Cysteine and methionine metabolism 8 1.87E-02 3.37E-01 2.07E+01
Prion diseases 8 2.18E-02 3.47E-01 2.37E+01
Lysosome 17 2.94E-02 4.05E-01 3.06E+01
One carbon pool by folate 5 3.73E-02 4.52E-01 3.72E+01
Antigen processing and presentation 13 3.80E-02 4.29E-01 3.77E+01
Pyruvate metabolism 8 4.25E-02 4.41E-01 4.12E+01
Purine metabolism 20 4.51E-02 4.37E-01 4.32E+01
Oocyte meiosis 15 6.63E-02 5.04E-01 5.68E+01
Pathways in cancer 34 1.29E-01 6.33E-01 8.16E+01
Ubiquitin mediated proteolysis 16 1.55E-01 6.63E-01 8.74E+01
Wnt signaling pathway 16 2.60E-01 7.31E-01 9.75E+01
MAPK signaling pathway 23 5.34E-01 8.58E-01 1.00E+02
Focal adhesion 15 7.85E-01 9.59E-01 1.00E+02
Regulation of actin cytoskeleton 15 8.59E-01 9.74E-01 1.00E+02
The ‘count’ column shows the number of significant genes identified within a pathway. Significant p-values (either the EASE score, the Benjamini-corrected or the FDR-
corrected p-values) are shown in bold.
doi:10.1371/journal.pone.0086699.t002
Table 3. Robustness analysis of the spliceosome pathway
enrichment.
DEG # threshold Count EASE score
2 (1 and 1) 30 2.15E-07
4 (2 and 2) 23 3.40E-05
6 (3 and 3) 14 4.10E-04
The strictness of the meta-analysis step was increased (selection of genes DEGs
in 2 datasets out of 16 available, then 4 datasets out of 16 and 6 datasets out of
16; the number between brackets represent the minimal number of datasets for
which the genes have to be DEG to be selected per biological group, i.e.
hypoxia or metastasis), the count of genes highlighted in the pathway (second
column) and EASE score given by DAVID (third column).
doi:10.1371/journal.pone.0086699.t003
A Bioinformatics Analysis of Micrarray Data
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Aim of this study
We propose to use a set of statistical and bioinformatics tools to
reanalyze metastasis and hypoxia-related data to gain further
insight into the processes involved. The comparison of two
analytical pipelines (ORA and FCS) is used to detect meaningful
pathways (a diagram of the analytical pipeline is shown in figure 1).
Moreover, this analysis rationale could be transposed to virtually
any biological situation with microarray data available.
Results and Discussion
A major biological topic of interest in our lab is the investigation
of expression profiles to describe common mechanisms between
metastasis and adaptation of cells to hypoxic conditions. PathEx
[47] was queried (performed on data present in PathEx in June
2012) with the keywords ‘‘hypoxia’’ and ‘‘metastasis’’ to identify
datasets available from Affymetrix HGU-133a and HGU-
133Plus2 arrays. We found 7 and 9 experiments focused on
hypoxia and metastasis respectively. The datasets selected (16) and
are listed and described in Table 1.
Meta-analysis and over-representation in pathways
In the first analytical step, the individual analyses of differential
expression for each dataset were performed using the Shrinkage t
methodology, which produced 16 lists of dataset-specific p-values.
Volcano plots are provided in figure 2 for two of the individual
datasets, to illustrate the distribution of significant values in a
separate analysis. The most interesting genes are usually identified,
in such graphs, in the upper left- and right-hand corners of the
plot, depicting genes with low p-values (Y-axis) and high fold
changes (X-axis). The meaning of the red dots is explained below.
A meta-analysis was performed in two steps to refine the list of
significant genes and to define a unique top list from the 16 lists of
p-values. Significant genes were first gathered from the two
categories of experiments, producing two lists of detected genes
(respectively specific to hypoxia and metastasis). The intersection
of both lists was then performed, as described in the materials and
methods section, to identify candidate genes expected to be
involved in both hypoxia and metastasis, while removing potential
false detections from the large lists retrieved in the first step. The
meta-analysis yielded substantially different results, as shown in
figure 2 by the repartition of red dots (final DEGs detected).
Table S1 provides the list of 1156 candidates identified in the
meta-analysis procedure, and figure 2 shows the scattering of the
candidates in volcano plots for 2 of the 16 datasets we analyzed.
The wide range of values observed in figure 2 is due to the
variability of the results between the 16 dataset-specific lists (p-
values), and the well-known under-estimation of fold changes in
microarray experiments [48]. Meta-analysis does not select the
most differentially expressed genes in single experiments. As we
selected the DEGs across different biological conditions, we can
hypothesize that they are representative of the common
components of the cellular responses to these situations, which
fits well with the purpose of this study.
The list of the identifiers for the 1156 genes obtained after the
meta-analysis step was then entered into the DAVID web tool. A
Figure 3. Plot of the EASE score and number of hits in the spliceosome pathway for the 500 random selections of 1156 gene
identifiers (in blue), compared with the actual result of the analysis (red). This graph plots the number of hits (X-axis) against the EASE
score (Y-axis). The difference between the random selection scores and the actual result score supports the assumption that the spliceosome is over-
represented in our list of genes.
doi:10.1371/journal.pone.0086699.g003
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total of 102 pathways containing at least 3 gene members of that
list was generated (see Table S2). Among these pathways, only 12
of them have an EASE score under the threshold of 0.05. This
number was further reduced to 3 pathways by applying a
correction for multiple testing (Benjamini correction) and only
one pathway (the spliceosome) was significant when applying a
correction based on the false discovery rate (FDR) (see Table 2).
However, the EASE score (and the corrected p-values derived
from it) should be interpreted with caution, according to the
biological relevance in the context studied, the wideness of the
pathways stored in the Kegg maps and the obvious rate of false
negatives induced by our screening. Many top list pathways,
although characterized by low EASE scores, are well-known to be
involved in metastatic processes and are therefore likely false
negatives: MAPK and Wnt signaling pathways, focal adhesion
pathway and the regulation of the actin cytoskeleton [49–52],
which corroborates the consistency of the mapping of significant
genes by our strategy. On the other hand, the robustness of the
spliceosome pathway with regards to the most stringent statistical
corrections supports the hypothesis of its implication in the process
studied.
To further assess the significance of the spliceosome pathway in
the over-representation results, we first performed 500 random
selections of 1156 EntrezGeneIDs among all the identifiers present
on the microarray and ran them in the DAVID tool. The EASE
scores and number of hits in the spliceosome pathway were then
plotted (see figure 3). The plot shows clearly the gap between the
random selections (with a maximum of 19 hits and an associated
EASE score of 0.0085) and the actual result (30 hits, EASE score
of 2E-7). Then, we analyzed the robustness of the discovery of the
spliceosome pathway by performing a more stringent selection in
the meta-analysis step (see Table 3). This table shows the EASE
score obtained for the spliceosome pathway when performing a
meta-analysis for genes differentially expressed in two (one in each
biological group), four (two in each group) or six (three in each
group) of the 16 datasets. The spliceosome pathway was largely
significant even in the most stringent selection (EASE score of 4E-
4). These comparisons tend to support the assumption that the
spliceosome pathway is actually over-represented in our meta-
analysis results.
Moreover, the spliceosome, whose implication in cancer has
been reported by several authors [53–55], has never been
described as specifically involved in metastasis, which is not
surprising based on the red dots in our volcano plots from single
analyses (figure 2). The spliceosome is a complex of RNA and
many protein subunits required for the splicing of pre-mRNA. It is
composed of five small nuclear RNA (snRNA) and numerous
associated protein factors. Proteins and snRNA form the RNA-
protein complexes (snRNP), called U1, U2, U4, U5 and U6 (see
figure 4). The list of genes detected as differentially expressed
contains genes coding for proteins that take part in the spliceosome
pathway (see Table S4). The results of our analysis identify genes
in all 5 snRNPs, reinforcing the hypothesis that this pathway plays
an important role in metastatic and hypoxic processes. The list of
genes detected as differentially expressed and their respective p-
values per dataset are presented in the Table 4.
Figure 4. Spliceosome units. The red stars mark the genes from our list mapped on this pathway.
doi:10.1371/journal.pone.0086699.g004
A Bioinformatics Analysis of Micrarray Data
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Table 5. Summary of FAERI results.
Gene set Name 5% Hypoxia 5% Metastasis % Total
KEGG_PATHWAYS_IN_CANCER 7 9 100
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 7 8 93.75
KEGG_PURINE_METABOLISM 7 8 93.75
KEGG_RIBOSOME 7 8 93.75
KEGG_PPAR_SIGNALING_PATHWAY 7 8 93.75
KEGG_MAPK_SIGNALING_PATHWAY 7 8 93.75
KEGG_ERBB_SIGNALING_PATHWAY 7 8 93.75
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 7 8 93.75
KEGG_CHEMOKINE_SIGNALING_PATHWAY 7 8 93.75
KEGG_ENDOCYTOSIS 7 8 93.75
KEGG_APOPTOSIS 7 8 93.75
KEGG_VEGF_SIGNALING_PATHWAY 7 8 93.75
KEGG_FOCAL_ADHESION 7 8 93.75
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 7 8 93.75
KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY 7 8 93.75
KEGG_HUNTINGTONS_DISEASE 7 8 93.75
KEGG_PANCREATIC_CANCER 7 8 93.75
KEGG_CHRONIC_MYELOID_LEUKEMIA 7 8 93.75
KEGG_RENAL_CELL_CARCINOMA 7 8 93.75
KEGG_CITRATE_CYCLE_TCA_CYCLE 6 8 87.5
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 7 7 87.5
KEGG_OXIDATIVE_PHOSPHORYLATION 6 8 87.5
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 6 8 87.5
KEGG_GLUTATHIONE_METABOLISM 6 8 87.5
KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 7 7 87.5
KEGG_PYRUVATE_METABOLISM 6 8 87.5
KEGG_RNA_DEGRADATION 6 8 87.5
KEGG_SPLICEOSOME 6 8 87.5
KEGG_CALCIUM_SIGNALING_PATHWAY 6 8 87.5
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 6 8 87.5
KEGG_CELL_CYCLE 6 8 87.5
KEGG_OOCYTE_MEIOSIS 6 8 87.5
KEGG_P53_SIGNALING_PATHWAY 6 8 87.5
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 6 8 87.5
KEGG_LYSOSOME 6 8 87.5
KEGG_MTOR_SIGNALING_PATHWAY 6 8 87.5
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION 6 8 87.5
KEGG_WNT_SIGNALING_PATHWAY 6 8 87.5
KEGG_AXON_GUIDANCE 6 8 87.5
KEGG_ECM_RECEPTOR_INTERACTION 6 8 87.5
KEGG_ADHERENS_JUNCTION 6 8 87.5
KEGG_TIGHT_JUNCTION 6 8 87.5
KEGG_GAP_JUNCTION 6 8 87.5
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 6 8 87.5
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 6 8 87.5
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 6 8 87.5
KEGG_JAK_STAT_SIGNALING_PATHWAY 6 8 87.5
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 6 8 87.5
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 6 8 87.5
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Gene set analysis
The second part of the analytical pipeline (figure 1) relies on the
inference of differentially expressed pathways in a gene set analysis
procedure (functional class scoring). Here, we used FAERI, a
multivariate procedure tailored from the two-way ANOVA
procedure. FAERI computes a gene set statistic from the
expression data of all member genes in a single step, and avoids
the loss of information inherent to 2-step procedures and the risk
of false negatives due to slight differences in all member genes (that
would not be individually detected in the first part of the pipeline).
In addition, FAERI relies on a self-contained procedure (label
sampling) that only requires the expression values of the set of
member genes (and not the complete dataset). Table 5 summarizes
the results obtained by individual analysis of the 16 selected
datasets conducted with FAERI. These results were then used to
compute, for each gene set, a ratio of discovery across all the
experiments (Table 5, third column). The definition of the sets was
retrieved from the C2.Kegg category of MsigDB (v3.0). The full
list of p-values is provided in Table S3.
Table 5 summarizes the information contained in Table S3 and
highlights the high number of differentially expressed sets across
both categories of experiments. The pathways identified by
FAERI are involved in glycolysis, neoglucogenesis, tricarboxylic
cycle, oxidative phosphorylation and other sugar metabolism
pathways. These results are relevant to the cell/tissue response to
hypoxic conditions. Here, only one gene set was detected across all
datasets: PATHWAYS_IN_CANCER. Many other cancer-re-
lated gene sets were detected in all but one experiment. Several
signaling pathways were also systematically called differentially
expressed, including PPAR, ERBB, MAPK, VEGF, P53, MTOR,
WNT, … The pathway for the regulation of the actin cytoskeleton
was also detected. The hypothesis of involvement of the
spliceosome is supported by 6 out of 7 datasets related to hypoxia
and 8 out of 9 datasets related to metastasis.
Both parts of the analytical pipeline described here have
detected the spliceosome pathway as involved in the hypoxic and
metastatic phenotypes. Among the 31 genes detected as differen-
tially expressed in this pathway, 11 have recently been shown to be
involved in the metastatic process (see Table 6). The remaining 20
genes are not yet known to be involved in these processes (see
Table 6, in bold). These results suggest that abnormal alternative
splicing regulation can modulate the metastatic potential of cancer
cells. Indeed, it is known that the recognition of splicing sites
depends on the protein composition of the spliceosome [56].
Dysregulated expression of the genes coding for these proteins
could therefore change the composition of the spliceosome
architecture, thus affecting the splicing process. A change in the
splicing process may influence the cell at all biochemical levels,
from the transcriptome to the proteome and even to the genome.
The 20 genes we have identified thus hold strong potential as
candidates for further studies.
The results also demonstrate the potential of sensitive and
specific analytical pipelines: new hypotheses can be proposed, and
previously known biological features can be used as positive
controls. However, comparison of the results between both parts of
the analytical pipeline suggests that the two analyses behave
differently: over-representation analysis of the most significant
genes across datasets detects some important pathways, and the
ability of gene set analysis using FAERI to detect slight cumulated
differences detects more pathways. Statistical analysis with FAERI
detects meaningful differences between samples, even when only
small numbers of replicates are available. Nevertheless, both parts
of the pipeline lead to detection of relevant information based on
current knowledge, and both suggest the involvement of the
spliceosome.
Table 5. Cont.
Gene set Name 5% Hypoxia 5% Metastasis % Total
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 6 8 87.5
KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY 6 8 87.5
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 6 8 87.5
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 6 8 87.5
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 6 8 87.5
KEGG_LONG_TERM_DEPRESSION 6 8 87.5
KEGG_ALZHEIMERS_DISEASE 6 8 87.5
KEGG_PARKINSONS_DISEASE 6 8 87.5
KEGG_VIBRIO_CHOLERAE_INFECTION 6 8 87.5
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION 6 8 87.5
KEGG_LEISHMANIA_INFECTION 6 8 87.5
KEGG_COLORECTAL_CANCER 6 8 87.5
KEGG_PROSTATE_CANCER 6 8 87.5
KEGG_MELANOMA 6 8 87.5
KEGG_BLADDER_CANCER 7 7 87.5
KEGG_ACUTE_MYELOID_LEUKEMIA 6 8 87.5
KEGG_SMALL_CELL_LUNG_CANCER 6 8 87.5
KEGG_VIRAL_MYOCARDITIS 6 8 87.5
The first column presents the name of the gene sets tested, the second and third columns show the number of times each gene set was detected as differentially
expressed at a threshold of 5% for the p-values, for each biological group. The last column contains the discovery rate across all experiments (7 hypoxia datasets and 9
metastasis datasets).
doi:10.1371/journal.pone.0086699.t005
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Conclusion and Perspectives
We implemented a pipeline of bioinformatics tools to explore
archived microarray data, from preprocessing to mapping of the
results. We used that pipeline to examine metastasis and hypoxia
data and found results in keeping with previous reports, as well as
a new hypothesis. The combination of high-level analysis (Over
Representation Analysis and Functional Category Scoring) with a
meta-analysis step led to the discovery of involvement of the
spliceosome in the hypoxic and metastatic processes, and the
generation of a list of 20 new candidate genes.
Bioinformatics approaches will never replace bench validations;
however we were able to form a plausible hypothesis just by re-
analyzing available data. Biological investigations should therefore
be performed to further refine the interpretation of the relation-
ships between the pathways detected and understand how a
hypoxic environment and metastasis affect both general and
energetic cell metabolism. Further investigations should be
conducted to clarify the results of the statistical analyses and to
discriminate between causes and consequences (mechanisms of
perturbations and symptoms). However, that validation is out of
the scope of this methodological paper.
We think that this analytical protocol could be used successfully
in many other biological contexts, wherever several datasets are
available. Indeed, we have shown that single gene analysis alone
yields poor results, though this is often the only step performed by
wet-lab biologists. The methodology presented here allows for
improved performance, comparison with previously known
information and discovery of recurrent patterns (through meta-
analysis), all of which were performed using freely-available
resources and software packages and without the need to perform
expensive de novo microarray experiments. We think that this work
will contribute to the creation of a virtual atlas for cellular biology
containing the known characteristics of cells in diverse biological
conditions, which is one of the major goals of the bioinformatics
community.
Table 6. List of the 31 genes highlighted in the spliceosome pathway.
Gene References in literature
DHX 15 NA
LSM6 NA
NAA38 NA
NHP2L1 NA
PRPF19 NA
RBM8A Kim et al, 2008 [60] and Salicioni et al, 2000 [61]
ACIN1 Lee et al, 2008 [62] and Shu et al, 2006 [63]
Cdc40 NA
CRNKL1 NA
HSPA1A NA
HSPA1B NA
HSPA8 NA
HNRNPA1P2 NA
HNRNPC Park et al, 2012 [64]
HNRNPK Inoue et al, 2007 [65] and Li et al, 2011 [66]
HNRNPM Palermo et al, 2012 [67] and Thomas et al, 2011 [68]
SNRPG NA
NCBP1 NA
PUF60 NA
SNRPD1 NA
SNRPD3 Cunha et al, 2010 [69]
SNRPEL1 NA
SNRPF NA
SF3B3 NA
SFRS1 Mukherji et al, 2006 [70], Hatakeyama et al, 2009 [71] and Meseguer et al, 2011 [72]
SFRS3 NA
SFRS5 Hatakeyama et al, 2009 [71]
SFRS7 Hatakeyama et al, 2009 [71]
SFRS9 Mukherji et al, 2006 [70]
TRA2B Watermann et al, 2006 [73]
USP39 NA
Eleven of those genes are previously known in the literature to be involved in metastasis (shown in grey), the 20 other are previously unknown (shown in bold) to be
involved in the metastatic process.
doi:10.1371/journal.pone.0086699.t006
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Methods
Selection and retrieval of datasets
For the purposes of the study reported here, two sets of criteria
were used to retrieve datasets with PathEx (described in [47]):
technological keywords to specifically retrieve Affymetrix Gene-
Chips HGU-133a and HGU-133plus2 array models; and
biological keywords to retrieve datasets that met the topics of
interest in this study: hypoxia or metastasis.
Entry of these technological and biological keywords into
PathEx resulted in a collection of 16 distinct datasets, as listed in
Table 1: 9 datasets specific to hybridizations performed on the
HGU-133a chip model, including 3 experimental designs
dedicated to hypoxia and 6 dedicated to metastasis; 7 datasets
obtained using the HGU-133plus2 array model, including 4
hypoxia-related and 3 metastasis-related experiments. The
number or replicated measurements ranged from 2 to 52
hybridizations (see Table 1). In addition, we preferred datasets
reporting in vivo gene expression levels and discarded data that
came from in vitro experiments.
Preprocessing and statistical analyses
The preprocessing of the data and the individual analyses
reported in this paper were performed using R 2.7 and 2.10,
available on the website of the R-Project (http://cran.r-project.
org), and a set of packages available in the Bioconductor repository
(http://www.bioconductor.org).
We used GCRMA to preprocess each of the 16 retrieved
datasets, in accordance with the performances reported in
previously reported benchmarks [26,57,58]. The summarization
step performed by GCRMA was guided by the affyprobeminer
transcript-consistent chip definition files (CDF) specific to the
HGU-133a and HGU-133plus2 chip models. The probe set
identifiers provided by alternative CDFs (affyprobeminer) differ
from the identifiers defined by the manufacturer of the arrays
(Affymetrix). Supplemental functions implemented in the affypro-
beminer packages were used to convert probe set identifiers into
EntrezGeneID. The identification of probe sets with EntrezGene
ID identifiers allowed us to compare the gene lists between HGU-
133a and HGU-133plus2 chip models, and to facilitate annotation
of the results from the individual analyses.
The differential expression of individual probe sets was analyzed
with the ’st’ package, which implements the Shrinkage t
methodology. This procedure was conducted on each dataset,
resulting in 16 dataset-specific lists of p-values, each p-value
referring to a specific probe set.
Meta-analysis, annotation, and gene set analysis
For each dataset, we selected the list of genes detected as
differentially expressed (p-value , 0.05). The 16 dataset-specific
lists of the most significant genes were gathered into two groups,
according to the experimental design (Hypoxia/Metastasis
studies). In each group of datasets, a new list of genes was defined
from the list of genes found to be differentially expressed in at least
one dataset of the group. Lastly, the intersection of the list of genes
from the two groups was performed by selecting genes that were
detected in both groups, resulting in a list of 1156 unique gene
identifiers (provided in Table S1, along with all the p-values
computed for the 16 datasets, p-values ranking for each dataset
and mean ranking across the 16 individual ranks).
The 1156 selected EntrezGene ID identifiers were mapped to
the Kegg Pathways database using the ‘‘Functional Annotation
Tools’’ available on the DAVID web interface [59]. Using
DAVID, 102 pathways, containing at least 3 of the 1156
candidate genes, were identified (see Table S2). To avoid biases
due to potential false positives, we selected for further analysis the
pathways that displayed a significant p-value (see Table 2).
Alongside the selection and annotation of the most significant
genes by the meta-analysis approach, differential expression
analyses of gene sets were conducted on each of the 16 datasets.
Gene set analyses were performed on preprocessed data in a single
step using the multivariate FAERI test. Gene set definitions were
retrieved from the MSigDB database (v3.0) [36]. We evaluated the
differential expression on gene sets belonging to the C.2 KEGG
category, composed of 186 curated pathways. Lastly, the 16
dataset-specific lists of p-values were used to compute, for each
gene set, the ratio of detection as differentially expressed across all
datasets. The full code for this analysis can be found in the Table
S5. For more details on the FAERI methodology, see [39].
The different steps in the analytical pipelines are summarized in
figure 1. The left part of the diagram contains the single gene
analysis steps (Shrinkage t test treatment, meta-analysis and over-
representation analysis (ORA) in DAVID). The right part contains
the gene set analysis steps (Functional Class Scoring (FCA) by
FAERI and meta-analysis of the results).
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